Login to Your Account

AMAG, Allos Claim 'Synergies' on Costs, Drug Sales in Merger

By Jennifer Boggs

Thursday, July 21, 2011
In what may be one of the more questionable mergers in biotech history, AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc., two firms that have little in common besides recently launched products that have underperformed commercially, agreed to combine in an all-stock deal valued at about $686 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription